QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Hawkeye who wrote (784)	12/16/1999 9:11:00 AM
From: BostonView	Read Replies (1) of 1321

Switzerland Is the First Country to Give Market Approval for Visudyne Therapy for AMD ATLANTA and VANCOUVER, British Columbia, Dec. 16 /PRNewswire/ -- CIBA Vision, the eye care unit of Novartis, and QLT PhotoTherapeutics Inc. (Nasdaq: QLTI; Toronto) announced today that the Swiss Regulatory Agency -- Interkantonale Kontrollstelle fur Heilmittel -- has given approval for the marketing of Visudyne (verteporfin) therapy, for the treatment of the wet form of age-related macular degeneration (AMD), the leading cause of blindness in people over the age of 50 in the western world. Specifically, the agency approved Visudyne for the treatment of wet AMD in patients with predominantly classic subfoveal choroidal neovascularization. Visudyne therapy will be made commercially available in Switzerland imminently. biz.yahoo.com BV

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next